In a population of 40 patients with coronary artery disease the overall incidence of spontaneous ischemic episodes during 24-h Holter monitoring could be significantly reduced with ISDN 120 mg ret. and ISDN 120 mg plus Diltiazem 120 mg ret. However, the intraindividual day-to-day variability of ischemic episodes on three consecutive days of Holter monitoring is taken into consideration, an intraindividual reduction of ischemic episodes of at least 97% is required to separate a true therapeutic effect from the considerable spontaneous variability.